孟鲁司特治疗支气管哮喘的临床研究

Clinical Study of Montelukast in the Treatment of Bronchial Asthma

目的分析孟鲁司特对支气管哮喘患者的治疗效果及影响,为临床提供参考。方法选取2016年1月~2017年1月我院收治的90例支气管哮喘患者,以随机数表法分成观察组与对照组,各45例。对照组予以常规治疗,观察组在常规治疗基础上加用孟鲁司特钠治疗,对比观察两组患者治疗总有效率、临床症状评分及不良反应情况。结果观察组患者临床治疗总有效率94.33%,高于对照组77.78%,差异有统计学意义(P<0.05);观察组临床症状评分(0.71±0.23)分,低于对照组(1.67±0.26)分,差异有统计学意义(P<0.05)。观察组不良反应率4.40%与对照组6.60%对比,差异无统计学意义(P>0.05)。结论孟鲁司特对支气管哮喘患者的治疗效果显著,与常规治疗相比,其不仅可有效提高临床疗效,而且可有效减少不良反应发生率,值得临床推广。

Objective To analyze the treatment effect and influence of montelukast on bronchial asthma patients and provide reference for clinical practice.Methods A total of 90 patients with bronchial asthma admitted to our hospital from January 2016 to January 2017 were randomly divided into observation group and control group,45 cases each.The control group was given routine treatment.The observation group was treated with montelukast sodium on the basis of conventional treatment.The total treatment efficacy,clinical symptom scores,and adverse reactions were compared between the two groups.Results The total effective rate of clinical treatment in observation group was 94.33%,which was higher than 77.78%in control group,the difference was statistically significant(P<0.05);the clinical symptom score of the observation group(0.71±0.23)was lower than that of the control group(1.67±0.26),and the difference was statistically significant(P<0.05).The adverse reaction rate in the observation group was 4.40%compared with 6.60%in the control group,with no statistically significant difference(P>0.05).Conclusion Montelukast has a significant therapeutic effect on bronchial asthma patients.Compared with conventional treatment,montelukast can not only effectively improve clinical efficacy,but also can effectively reduce the incidence of adverse reactions and is worthy of clinical promotion.